May 18, 2021
Takeda Pharmaceutical unit Baxalta will stop fighting the $173 million in damages it was hit with two years ago for infringing Bayer's patent covering a hemophilia treatment after the two drugmakers managed to work out a deal, a Delaware federal court heard Tuesday.
August 26, 2019
A Delaware federal judge on Monday shot down Bayer's bid to collect attorney fees in a case against a Takeda Pharmaceutical unit, though the company did win additional damages on top of a jury verdict earlier this year directing the rival drugmaker to pay $155 million for infringing Bayer's hemophilia treatment patent.
August 23, 2019
A Delaware federal judge on Friday denied a bid from a Takeda Pharmaceutical unit to throw out a jury's verdict saying the company owes $155 million for infringing Bayer's hemophilia treatment patent and refused to call for a new trial.
March 08, 2019
A Takeda Pharmaceutical unit urged a Delaware federal court Friday to throw out a jury's $155 million verdict for infringing Bayer's hemophilia treatment patent, while Bayer asked the judge in a separate motion to tack on $27 million more in supplemental damages and interest.
February 25, 2019
Bayer pushed a Delaware federal court Friday to have a Takeda Pharmaceutical unit cover its legal costs on top of its $155 million jury verdict for patent infringement of a hemophilia treatment, arguing the case was "exceptional" because of its opponent's "refusal" to follow court instructions.
February 05, 2019
Following more than a week of trial in Delaware, a federal jury has said a Takeda Pharmaceutical Co. Ltd. unit should pay $155 million in royalties to Bayer Healthcare LLC for infringing a hemophilia treatment patent.